Lazard Asset Management LLC Vir Biotechnology, Inc. Transaction History

Lazard Asset Management LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$9.14 - $24.62 $4,953 - $13,344	542 Added 43.12%	1,799 $16,000
Q2 2023 Aug 14, 2023	SELL	$23.2 - $27.29 $76,884 - $90,439	-3,314 Reduced 72.5%	1,257 $30,000
Q1 2023 May 15, 2023	BUY	$22.26 - $30.85 $4,763 - $6,601	214 Added 4.91%	4,571 $106,000
Q4 2022 Feb 14, 2023	BUY	$19.96 - $28.22 $86,965 - $122,954	4,357 New	4,357 $110,000
Q2 2022 Aug 09, 2022	BUY	$19.08 - $26.7 $5,342 - $7,476	280 Added 7.64%	3,943 $100,000
Q1 2022 May 13, 2022	BUY	$21.19 - $40.01 $76,940 - $145,276	3,631 Added 11346.88%	3,663 $94,000
Q4 2021 Feb 09, 2022	SELL	$30.97 - $54.03 $37,721 - $65,808	-1,218 Reduced 97.44%	32 $1,000
Q3 2021 Nov 15, 2021	BUY	$34.9 - $54.54 $43,625 - $68,175	1,250 New	1,250 $54,000
Q4 2020 Feb 11, 2021	SELL	$25.51 - $43.38 $6,173 - $10,497	-242 Closed	0 $0
Q3 2020 Nov 13, 2020	BUY	$28.28 - $53.6 $6,843 - $12,971	242 New	242 $8,000

218

87M

127K

1.19M

Ticker VIR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 132,638,000
Market Cap $982M
Description
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 fo...

Get notified when there are updates to the investment portfolio of Lazard Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Lazard Asset Management LLC with notifications on news.